Pre-treatment Haemoglobin and Peripheral Blood Lymphocyte Count as Independent Predictors of Outcome in Carcinoma of Cervix

Clinical Oncology

Volumn 26, Issue 4, 2014, Pages 179-184

  Hoskin, P J ^a   Rojas, A M ^a   Peiris, S N ^a   Mullassery, V ^a   Chong, I Y ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Cervix cancer; Haemoglobin; Lymphocyte count; Outcome; Prognostic biomarkers

Indexed keywords

CISPLATIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VERY ELDERLY; YOUNG ADULT; BLOOD; CANCER STAGING; METABOLISM; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMOGLOBINS; HUMANS; LYMPHOCYTE COUNT; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84895436218     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.11.023     Document Type: Article

References (40)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001, 91(12):2214-2221.
3. Harrison L.B., Chadha M., Hill R.J., Hu K., Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7(6):492-508.
4. Girinski T., Pejovic-Lenfant M.H., Bourhis J., et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989, 16(1):37-42.
5. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999, 86(8):1528-1536.
6. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 2001, 28(2 Suppl. 8):60-65.
7. West C.M., Davidson S.E., Roberts S.A., Hunter R.D. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997, 76(9):1184-1190.
8. Vaupel P., Hockel M., Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007, 9(8):1221-1235.
9. Bishara S., Griffin M., Cargill A., et al. Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2008, 138(1):71-75.
10. Ceze N., Thibault G., Goujon G., et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 2011, 68(5):1305-1313.
11. Choi C.H., Kang H., Kim W.Y., et al. Prognostic value of baseline lymphocyte count in cervical carcinoma treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2008, 71(1):199-204.
12. Claude L., Perol D., Ray-Coquard I., et al. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol 2005, 76(3):334-339.
13. Kitayama J., Yasuda K., Kawai K., Sunami E., Nagawa H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 2011, 11:64.
14. Lee Y.T. Peripheral lymphocyte count and subpopulations of T and B lymphocytes in benign and malignant diseases. Surg Gynecol Obstet 1977, 144(3):435-450.
15. Molling J.W., Langius J.A., Langendijk J.A., et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007, 25(7):862-868.
16. Ohwada S., Iino Y., Nakamura S., et al. Peripheral blood T cell subsets as a prognostic factor in gastric cancer. Jpn J Clin Oncol 1994, 24(1):7-11.
17. Ray-Coquard I., Cropet C., Van Glabbeke M., et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009, 69(13):5383-5391.
18. Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 1970, 25(1):135-140.
19. Vicente Conesa M.A., Garcia-Martinez E., Gonzalez Billalabeitia E., et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast 2012, 21(4):468-474.
20. Yasuda K., Sunami E., Kawai K., Nagawa H., Kitayama J. Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer. J Gastrointest Cancer 2012, 43(2):236-243.
21. Yu Q.M., Yu C.D., Ling Z.Q. Elevated circulating CD19+ lymphocytes predict survival advantage in patients with gastric cancer. Asian Pac J Cancer Prev 2012, 13(5):2219-2224.
22. Borg C., Ray-Coquard I., Philip I., et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004, 101(11):2675-2680.
23. Choi C.W., Sung H.J., Park K.H., et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 2003, 73(4):263-266.
24. Huehnergarth K.V., Mozaffarian D., Sullivan M.D., et al. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol 2005, 95(12):1492-1495.
25. Peron J., Cropet C., Tredan O., et al. CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer 2012, 49:1080-1089.
26. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47.
27. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-732.
28. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012, 33(4):207-214.
29. Burri P., Djonov V., Aebersold D.M., et al. Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56(2):494-501.
30. Dellas K., Bache M., Pigorsch S.U., et al. Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 2008, 184(3):169-174.
31. Palazon A., Aragones J., Morales-Kastresana A., de Landazuri M.O., Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res 2012, 18(5):1207-1213.
32. Spacek L.A., Griswold M., Quinn T.C., Moore R.D. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS 2003, 17(9):1311-1317.
33. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11(6):393-410.
34. Hoskin P.J., Rojas A.M., Bentzen S.M., Saunders M.I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010, 28(33):4912-4918.
35. Janssens G.O., Rademakers S.E., Terhaard C.H., et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012, 30(15):1777-1783.
36. Rojas A., Hirst V.K., Calvert A.S., Johns H. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy. Int J Radiat Oncol Biol Phys 1996, 34(2):357-365.
37. Airley R.E., Loncaster J., Raleigh J.A., et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 2003, 104(1):85-91.
38. Buffa F.M., Harris A.L., West C.M., Miller C.J. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010, 102(2):428-435.
39. Toustrup K., Sorensen B.S., Alsner J., Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012, 22(2):119-127.
40. Vozenin M.C., Lord H.K., Hartl D., Deutsch E. Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity. Cancer Treat Rev 2010, 36(8):629-636.